News | Peripheral Artery Disease (PAD) | August 24, 2016

Positive TOBA Mini Stent Tacking System One-Year Results Published

First large-scale, multicenter clinical trial data demonstrates safety and efficacy of the Tack Endovascular System

Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery

August 24, 2016 — Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical study were published in the July 2016 edition of the Journal of Vascular Surgery.

The TOBA study enrolled 138 subjects at 13 sites in Europe. All study participants were suffering from peripheral artery disease caused by blockages in the superficial femoral or popliteal arteries, which are located in the upper part of the leg. All participants underwent percutaneous balloon angioplasty (PTA) with any dissections (or tears) resulting from PTA repaired using the Tack Endovascular System.

The Tack implant is a new technology designed to repair dissections in the artery wall that frequently occur as a complication during PTA. The system allows physicians to repair these dissections while leaving a minimal amount of foreign material in the artery, which reduces mechanical stress on the artery; leaves the artery in its most natural state; and preserves future treatment options. If the dissections are left unrepaired, they increase the probability of acute artery occlusion or may continue narrowing the artery.

Some key conclusions from the TOBA study included:

  • 98.5 percent of participants achieved technical success;
  • 76.4 percent 12-month primary patency;
  • 89.5 percent freedom from target lesion revascularization (TLR); and
  • 82.8 percent participants had a Rutherford Classification grade ≤1 at 12 months, representing a significant improvement in function from baseline.

Marc Bosiers, M.D., A.Z. St. Blasius Hospital, Dendermonde, Belgium, was the principal investigator for the TOBA study. Bosiers stated, “These one-year results from the TOBA study demonstrate that the minimal metal approach associated with the Tack implant produces positive, lasting results in patients with severe peripheral artery disease. This is a high-cost, resource-intensive disease, so treatments with long-term effectiveness, such as combining angioplasty with the Tack implant, bring substantial benefits for patients and payers alike.”

Peter Schneider, M.D., chief of vascular at the Kaiser Foundation Hospital in Honolulu, Intact Vascular’s co-founder and chief medical officer, added, “This first, large-scale study investigating the safety and efficacy of the Tack Endovascular System is a key building block for the broad clinical development program we are pursuing at Intact Vascular. Plain PTA in this setting typically has a one-year patency rate of 30-55 percent. When we added the Tack device to the treatment, the one-year success was improved to 76.4 percent. Our next studies involve combining the Tack system with drug-coated balloon angioplasty, which is the focus of our TOBA II and III clinical trials.”

Based on these results, Intact Vascular has been enrolling participants in an expanded study, TOBA II  that is being conducted at more than 35 U.S. and European centers under an Investigational Device Exemption (IDE) approval. The company plans to submit data from TOBA II in support of a pre-market approval application with the U.S. Food and Drug Administration (FDA).

Recently, the company commenced enrollment in TOBA III, a post-CE Mark study conducted in Europe to assess the combination of the Tack implant and drug-coated balloon angioplasty in the superficial femoral and popliteal arteries.

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init